The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology firm focused on neurogenetic medicines with a market capitalization of $290 million, announced today it is reassessing its ...

With this acquisition, LipoVation becomes a wholly owned subsidiary of Revium Rx, aligning with the company’s renewed commitment to drug delivery innovation. Revium Rx is developing a portfolio of ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

Pham, Chief Executive Officer, Cadrenal Therapeutics ... therapy as well as other business development opportunities to build the Company’s pipeline, as well as advancing other indications ...

Johnson & Johnson is contributing $1 million to support the development of curricula and modernization of training and lab ...

Successful launch of sepiapterin would also validate PTC Therapeutics' development capabilities and potentially increase investor confidence in the company's broader pipeline. This could lead to a ...